

## Curriculum Vitae

# Personal information Panagiota Tsantili

#### Work experience

- Employer: National Organization for Medicines
   Start date: 06-2009
  - - End date:
  - Position: Deputy Head, Section of Biological Products, Evaluation Division (October 2023 )
  - Activities: Quality, Non\_Clinical and Clinical assessment of biological products [Biologicals of recDNA origin, Neurotoxins, Blood products (Coagulation factors, Intravenous) Immunoglobulins), Vaccines].
  - Scientific Board of approvals for Biological products (national applications): Scientific Secretary (October 2018-June 2023).
  - Biosimilar Medicinal Products Working Party (BMWP) Observer Appointment: October 2010 -May 2023.

    • Biologics Working Party (BWP) Alternate member: June 2014 - March 2023. Member: June
  - 2023-present.

     HMA, Biosimilar Working Group (BSWG) Member : Sept. 2021- present
- Country: Greece
  Employer: Ministry of Health and Social Solidarity
  Start date: 10-2006
  End date: 06-2009
  Position: Division of Medicines and Pharmacies

  - Activities: Pharmacist, Section of Opioid Analgesics
  - Country: Greece
- 3. Employer: Technological Educational Institute of Athens (TEI), Dept. of Medical Laboratories.
  - Start date: 09-2003 End date: 06-2005

  - Position: Teaching position, (Associate Professor level)
    - Activities: Course in Biology
  - Country: Greece
- Employer: Massachusetts General Hospital\_Harvard Medical School, Dept. of Surgery,Antibody Engineering Laboratory \_ Boston, MA
  - Start date: 02-2000
  - End date: 11-2001
  - Position: Post\_Doctoral Research Fellow.
  - Activities: Refinement of recombinant antibody structure for immunotherapy. Insertional mutagenesis in CDR loops to modify the specificity of antidigoxin Fab fragments. Identification of antigenic epitopes of Streptokinase (SK).
  - Country: United States
- 5. Employer: Boston University School of Medicine, Section of Molecular Genetics, Cardiovascular Institute, Boston, MA
  - Start date: 04-1998

  - End date: 01-2000 Position: Post\_Doctoral Research Fellow
  - Activities: Structure\_function analysis of the transcription activation domains of Hepatocyte Nuclear Factor 4
  - Country: United States

#### Education and training

- National & Kapodistrian University of Athens, Department of Biology
   Start date: 08-1993

  - End date: 04-1998 Qualification: Ph.D. Degree
  - Ph.D. thesis title: "Recombinant Monoclonal Antibodies against the Acetylcholine Receptor" . Molecular mechanisms of autoimmunity, pathopysiology of Myasthenia Gravis, generation and biological characterization of recombinant mAb fragments, structural analysis of mAbs for receptor binding, AChR receptor\_mAb interactions
- Country: Greece
   Aristotle University of Thessaloniki, Department of Chemistry, Section of Biochemistry.
  - Start date: 07-1991 End date: 10-1992

  - Qualification: Research Assistant
    Project title: "Establishment of Assay Conditions for Human Pancreatic Lipase". Lipase activity determination, enzyme purification techniques
- Country: Greece
  3. Aristotle University of Thessaloniki, Department of Pharmacy.

  - Start date: 09-1987 End date: 07-1991
  - Qualification: Bachelor Degree in Pharmacy Country: Greece

TRAINING

- 1. Subject: BMWP/BWP joint assessors training on assessment of similar biological medicinal products containing monoclonal antibodies
  - Start date: 10-2012 Qualification: Training Organisation: EMA Country: United Kingdom
- 2. Subject: Dendrimers as Composites of Advanced Drug Delivery nano Systems (aDDnSs): Biomedical Applications
  - Start date: 10-2011

  - Qualification: Training School and workshop
    Organisation: National and Kapodistrian University of Athens, Dept. of Pharmacy, National Research Foundation, Athens

  - Country: Greece
- 3. Subject: Blood Products Assessors training (BPWP) Webinar
  - Start date: 09-2011 Qualification: Training Organisation: EMA
- Country: United Kingdom
   Subject: Assessor's Training on Advance Therapy Medicinal Products

  - Start date: 04-2011
    Qualification: Training
    Organisation: EMA
- Country: United Kingdom
   Subject: Common Assessment Framework: Total Quality Management Tool
  - Start date: 03-2011
  - Oualification: Training
  - Organisation: National Centre for Public Administration & Local Government (E.K.D.D.A.), Athens
  - Country: Greece
- 6. Subject: FEBS "ADVANCED COURSE ON GENE THERAPY"

   Start date: 10-1995
  - Qualification: Training Organisation: FEBS course Country: Varena, Italy
- 7. Subject: Advanced Study Course "MOLECULAR MECHANISMS OF TRANSCELLULAR SIGNALLING: From the Membrane to the Gene.
  - Start date: 08-1994
  - Qualification: Training Organisation: "FEBS/NATO Summer School,
  - Country: Spetsai, Greece

#### Additional information

#### **Publications**

- 1 . Kurki P, Barry S, Bourges I, Tsantili P, Wolff\_Holz E. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Drugs. 2021 Oct 1. doi: 10.1007/s40265 021 01601 2
- 2. Aggelidou E, Iordanidou P, Tsantili P, Papadopoulos G, Hadzopoulou\_Cladaras M. Critical role of residues defining the ligand binding pocket in hepatocyte nuclear factor\_4a (HNF\_4a). J Biol Chem. 2004 Jul 16; 279 (29): 30680\_5.
- 3. Parhami\_Seren B, Seavey M, Krudysz J, Tsantili P. Structural correlates of a functional streptokinase antigenic epitope: serine 138 is an essential residue for antibody binding. J Immunol Methods. 2003 Jan 15;272(1\_2):93\_105.
- 4. Krykbaev RA, Tsantili P, Jeffrey PD, Margolies MN. Modifying specificity of antidigoxin antibodies using insertional mutagenesis. Protein Sci. 2002 Dec;11 (12):2899\_908.
- 5. Hadzopoulou\_Cladaras M, Aggelidou E, Iordanidou P, Tsantili P. Mutations in the ligand binding domain (LBD) of hepatocyte nuclear factor 4 alpha (HNF\_4 alpha) affect transcriptional activation and coactivator interaction. Circulation, Nov. 5 2002;106 (19): 832 Supplement
- 6. Parhami\_Seren B, Krudysz J, Tsantili P. Affinity panning of peptide libraries using anti\_streptokinase monoclonal antibodies: selection of an inhibitor of plasmin(ogen) active site. J Immunol Methods. 2002 Sep 15;267(2):185.
- 7. Kardassis D, Falvey E, Tsantili P, Hadzopoulou\_Cladaras M, Zannis V. Direct physical interactions between SP1 and HNF\_4 mediate synergistic transactivation of the Apolipoprotein C III promoter. Biochemistry. 2002 Jan 29;41(4):1217\_28
- 8. Kistanova E, Dell H, Tsantili P, Falvey E, Cladaras C, Hadzopoulou\_Cladaras M. The AF\_1 domain of HNF\_4 is an acidic activator that mediates interactions through bulky hydrophobic residues. Biochem. J, 2001;356:635\_42.
- 9\*. Poulas K, Tsibri E, Kokla A, Papanastasiou D, Tsouloufis T, Marinou M, Tsantili P, Papapetropoulos T, Tzartos SJ. Epidemiology of myasthenia gravis in Greece. J of Neurol Neurosurg Psychiatry 2001;71:352\_56.
- 10. Kardassis D, Falvey E, Tsantili P, Hadzopoulou\_Cladaras M, Zannis V. Direct physical interactions between SP1 and HNF 4 mediate synergistic transactivation of the Apolipoprotein CIII promoter. Circulation, Oct 31 2000; 102 (18): 1440 Supplement
- 11. Kontou M, Leonidas DD, Vatzaki EH, Tsantili P, Mamalaki A, Oikonomakos NG, Acharya KR, Tzartos SJ. The crystal structure of the Fab fragment of a rat monoclonal antibody against the main immunogenic region of the human muscle acetylcholine receptor. Eur J Biochem. 2000;267(8):2389\_97.
- 12. Poulas K, Tsibri E, Papanastasiou D, Tsouloufis T, Marinou M, Tsantili P, Papapetropoulos T, Tzartos SJ. Equal male and female incidence of myasthenia gravis. Neurology. 2000;54(5):1202\_3.
- 13. Tsantili P, Tzartos SJ, Mamalaki A. High affinity antibody fragments protecting the human nicotinic acetylcholine receptor. J. Neuroimmunol 1999;94:15\_28.
- 14. Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, Papanastasiou D, Sakarellos C, Sakarellos\_Daitsiotis M, Tsantili P, Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle type nicotinic acetylcholine receptor. Immunol Rev. 1998 Jun;163:89 120
- 15. Tzartos SJ, Tsantili P, Papanastasiou D, Mamalaki A, Construction of single chain Fy fragments of anti MIR monoclonal antibodies. Ann N Y Acad Sci. 1998;841:475\_7
- 16. Tsantili P., Mamalaki A. and Tzartos S Construction of a single chain Fv antibody (scFv195) fragment against the human Acetylcholine receptor. Contribution of light chain amino acid residues in receptor recognition". Immunology Letters 1997 May; 56 (Part 2)
- 17. Tzartos SJ, Cung MT, Mamalaki A, Marraud M, Papanastasiou D, Sakarellos C, Sakarellos\_Daitsiotis M, Tsantili P.

Antigenic structure of the muscle nicotinic acetylcholine receptor. Ann Med Interne. 1996, 147(6):442\_6

18. Arzoglou P, Goudoula C, Tsantili P, Lessinger JM, Ferard G, Mignot V, Samyn N, Demeester J, Lauwers A, Brettschneider H, et al. Transferability of lipase titrimetric assays: deductions from an interlaboratory study. Eur J Clin Chem Clin Biochem 1994;32(10):773\_7

\* Authors of the manuscript are recipients of Honorary Award from National and Kapodistrian University of Athens.

## **Projects**

### Memberships

Other Relevant Information

LANGUAGES: GREEK (native speaker) OTHER LANGUAGES: ENGLISH Excellent (reading, writing and verbal skills)

Page 3 of 3